CFTR and cystic fibrosis: VX-770 is a small molecule with the ability to potentiate (increase channel gating and open probability) CFTR, and it was initially shown to be effective in improving the chloride conductance of CF-causing mutant CFTRs that have a defect in gating, including G551D and the most common mutation, F508del [1].